G1 Therapeutics Inc (G1 Therapeutics) is a biopharmaceutical company. It discovers, develops and commercializes therapeutics for the treatment of cancer. The company offers pipeline products that include COSELA (trilaciclib), a CDK4/6 inhibitor to preserve hematopoietic stem cell and immune system function during chemotherapy, lerociclib and G1T48, an oral selective estrogen receptor degrader. G1 Therapeutics discovers new small molecule-based methods that prevent the hematological side effects of cancer chemotherapy and exposure to ionizing radiation. The company also develops small molecules to target specific proteins associated with cell proliferation and growth. It operates through its laboratory located in Research Triangle Park. G1 Therapeutics is headquartered in Research Triangle Park, North Carolina, the US.
Headquarters
United States of America
Address
700 Park Offices Drive, Suite 200, Research Triangle Park, North Carolina, 27709
Website
www.g1therapeutics.com
Telephone
1 919 2139835
No of Employees
100
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
GTHX (NASD)
Revenue (2022)
$82.5M
60.8%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
67.5%
(2022 vs 2021)
Market Cap*
$194.2M
Net Profit Margin (2022)
XYZ
79.8%
(2022 vs 2021)
* As of and is in US$
Products and Services
| Products |
|---|
| Pipeline |
| COSELA (Trilaciclib) |
| Lerociclib |
| XYZ |
| XYZ |
| XYZ |
Competitor Comparison
| Key Parameters | G1 Therapeutics Inc | Aclaris Therapeutics Inc | Surface Oncology Inc | Chinook Therapeutics Inc | Abeona Therapeutics Inc |
|---|---|---|---|---|---|
| Headquarters | United States of America | United States of America | United States of America | United States of America | United States of America |
| City | Research Triangle Park | Wayne | Cambridge | Seattle | Cleveland |
| State/Province | North Carolina | Pennsylvania | Massachusetts | Washington | Ohio |
| No. of Employees | 100 | 91 | 60 | 214 | 84 |
| Entity Type | Public | Public | Private | Private | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Garry A Nicholson | Chairman | Executive Board | 2018 | 68 |
| John E Bailey | Chief Executive Officer; Director | Executive Board | 2021 | 58 |
| John W Umstead V | Chief Financial Officer | Senior Management | 2023 | 38 |
| Terry L Murdock | Chief Operating Officer | Senior Management | 2019 | 62 |
| Monica Thomas | Chief Compliance Officer; General Counsel | Senior Management | 2023 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer